TABLE 2.
Acute Enva | Subtype | Fold inhibition by SERINC5b | Fold inhibition by IFITM3c |
---|---|---|---|
CRF02_AG clone 235 | A/G | 1.13 ± 0.55 | 1.57 ± 0.25 |
CRF02_AG clone 242 | A/G | 2.08 ± 0.64 | 6.83 ± 1.19 |
CRF02_AG clone 250 | A/G | 9.18 ± 0.32 | 4.75 ± 1.54 |
CRF02_AG clone 251 | A/G | 0.54 ± 0.11 | 2.28 ± 0.51 |
Subtype G clone 252 | A/G | 0.41 ± 0.09 | 5.8 ± 0.66 |
CRF02_AG clone 255 | A/G | 1.74 ± 0.56 | 3.41 ± 0.88 |
CRF13_cpx clone 258 | A/G | 0.77 ± 0.11 | 1.7 ± 0.46 |
CRF02_AG clone 263 | A/G | 2.24 ± 0.66 | 8.06 ± 2.49 |
CRF02_AG clone 266 | A/G | 1.43 ± 0.24 | 4.57 ± 0.06 |
CRF02_AG clone 269 | A/G | 2.06 ± 0.60 | 2.78 ± 0.19 |
CRF02_AG clone 271 | A/G | 1.11 ± 0.18 | 11.61 ± 0.75 |
CRF02_AG clone 278 | A/G | 1.37 ± 0.40 | 14.7 ± 1.84 |
CRF02_AG clone 928 | A/G | 1.91 ± 0.07 | 10.67 ± 0.002 |
6535, clone 3 (SVPB5) | B | 11.83 ± 1.98 | 4.69 ± 0.54 |
PVO, clone 4 (SVPB11) | B | 0.96 ± 0-0.04 | 1.98 ± 0.13 |
TRO, clone 11 (SVP. B12) | B | 0.37 ± 0.03 | 5.66 ± 0.63 |
AC10.0, clone 29 (SVPB13) | B | 0.60 ± 0.15 | 6.50 ± 1.51 |
pREJO4541 clone 67 (SVPB16) | B | 3.86 ± 0.56 | 4.82 ± 0.67 |
pRHPA4259 clone 7 (SVPB14) | B | 2.177 ± 0.49 | 15.56 ± 1.0 |
pCAAN5342 clone A2 (SVPB19) | B | 0.71 ± 0.018 | 3.98 ± 0.40 |
Du156.12 | C | 1.17 ± 0.33 | 1.26 ± 0.20 |
Du172.17 | C | 1.40 ± 0.55 | 1.05 ± 0.005 |
ZM197M.PB7 | C | 4.26 ± 2.33 | 0.98 ± 0.09 |
ZM214M.PL15 | C | 2.28 ± 0.50 | 2.97 ± 0.39 |
ZM249M.PL1 | C | 2.84 ± 1.30 | 1.21 ± 0.03 |
ZM53M.PB12 | C | 1.58 ± 0.54 | 1.22 ± 0.14 |
ZM109F.PB4 | C | 5.10 ± 1.71 | 12.30 ± 0.63 |
ZM135M.PL10a | C | 3.87 ± 1.40 | 4.53 ± 0.64 |
CAP45.2.00.G3 | C | 5.00 ± 1.92 | 1.55 ± 0.17 |
CAP210.2.00.E8 | C | 2.46 ± 0.10 | 5.85 ± 0.14 |
HIV-001428-2 clone 42 | C | 1.04 ± 0.06 | 8.19 ± 0.52 |
HIV-16845-2 clone 22 | C | 0.95 ± 0.08 | 9.13 ± 0.39 |
HIV-16936-2 clone 21 | C | 1.57 ± 0.15 | 10.96 ± 0.70 |
HIV-25711-2 clone 4 | C | 3.80 ± 0.27 | 7.81 ± 0.04 |
HIV-25925-2 clone 22 | C | 1.52 ± 0.03 | 15.64 ± 4.07 |
All the Env clones are R5 tropic.
Fold inhibition by SERINC5 was determined by calculating the ratio of infectivity of the SERINC5-free virus to that of the SERINC5-bearing virus.
Fold inhibition by IFITM3 was determined by calculating the ratio of infectivity of the IFITM3-free virus to that of the IFITM3-bearing virus.